{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:01:39Z","timestamp":1782255699381,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.urolonc.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T02:00:42Z","timestamp":1478138442000},"page":"14-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["A review of the PD-1\/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment"],"prefix":"10.1016","volume":"35","author":[{"given":"Tian C.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Sankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Porcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Perlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P.","family":"Schoenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxing","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2016.10.004_bib1","unstructured":"Howlader N, Noone AM, Krapcho M: SEER Cancer Statistics Review, April 2015 ed. Bethesda: National Cancer Institute; 1975\u20132012."},{"key":"10.1016\/j.urolonc.2016.10.004_bib2","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/357011a0","article-title":"Coley\u2019s toxins in perspective","volume":"357","author":"Starnes","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.004_bib4","first-page":"97","article-title":"Cancer and tuberculosis","volume":"9","author":"Raymond","year":"1929","journal-title":"Am J Hygiene"},{"issue":"Suppl. 5","key":"10.1016\/j.urolonc.2016.10.004_bib5","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1038\/184291a0","article-title":"Effect of bacillus Calmette-Guerin infection on transplanted tumours in the mouse","volume":"184","author":"Old","year":"1959","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.004_bib6","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0140-6736(73)90423-6","article-title":"BCG in malignant melanoma","volume":"1","author":"Baker","year":"1973","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2016.10.004_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.juro.2007.08.122","article-title":"History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story","volume":"179","author":"Herr","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2014a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib11","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0022-5347(05)65157-9","article-title":"Contemporary management of stage T1 transitional cell carcinoma of the bladder","volume":"167","author":"Soloway","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib12","first-page":"281","article-title":"Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer","volume":"10","author":"Grossman","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.eururo.2014.11.031","article-title":"Therapeutic options in high-risk non-muscle-invasive bladder cancer during the current worldwide shortage of bacille Calmette-Guerin","volume":"67","author":"Mostafid","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib14","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1471-4906(01)01896-8","article-title":"The role of MHC class II-restricted tumor antigens and CD4+T cells in antitumor immunity","volume":"22","author":"Wang","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/bjc.1996.28","article-title":"Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer","volume":"73","author":"Korkolopoulou","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2016.10.004_bib16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jnci\/87.4.280","article-title":"Molecular characterization of defective antigen processing in human prostate cancer","volume":"87","author":"Sanda","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2016.10.004_bib17","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1158\/1078-0432.CCR-06-2450","article-title":"T-cell distribution and adhesion receptor expression in metastatic melanoma","volume":"13","author":"Weishaupt","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.004_bib18","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.201398198","article-title":"Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors","volume":"98","author":"Medema","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.urolonc.2016.10.004_bib19","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.urolonc.2016.10.004_bib20","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-07-1030","article-title":"The B7 family and cancer therapy: costimulation and coinhibition","volume":"13","author":"Zang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.004_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib22","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184\u2013043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib23","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2016.10.004_bib24","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib25","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"10.1016\/j.urolonc.2016.10.004_bib26","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/PPO.0000000000000059","article-title":"Biochemical signaling of PD-1 on T cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.urolonc.2016.10.004_bib27","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.urolonc.2016.10.004_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.urolonc.2016.10.004_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.004_bib30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.004_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.acthis.2006.01.003","article-title":"Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance","volume":"108","author":"Wu","year":"2006","journal-title":"Acta Histochem"},{"key":"10.1016\/j.urolonc.2016.10.004_bib32","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1158\/0008-5472.CAN-05-4303","article-title":"Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up","volume":"66","author":"Thompson","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.004_bib33","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/1078-0432.CCR-04-0428","article-title":"B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression","volume":"10","author":"Konishi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.004_bib34","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.24899","article-title":"Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma","volume":"116","author":"Hino","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.10.004_bib35","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.24","article-title":"A phase 1B study of pembrolizumab (Pembro; MK-3475) in patients with advanced urothelial tract cancer","volume":"25","author":"Plimack","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib36","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2016.10.004_bib37","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S1470-2045(10)70086-3","article-title":"Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium","volume":"11","author":"Sonpavde","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib38","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib39","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2016.10.004_bib40","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","article-title":"T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival","volume":"14","author":"Boorjian","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2016.10.004_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2016.10.004_bib42","doi-asserted-by":"crossref","first-page":"703 e1","DOI":"10.1016\/j.urology.2014.10.020","article-title":"Assessment of tumoral PD-L1 expression and intratumoral CD8+T cells in urothelial carcinoma","volume":"85","author":"Faraj","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2016.10.004_bib43","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/annonc\/mdv009","article-title":"Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma","volume":"26","author":"Bellmunt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","article-title":"Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder","volume":"40","author":"Xylinas","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urolonc.2016.10.004_bib45","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","article-title":"Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.urolonc.2016.10.004_bib46","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","article-title":"PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression","volume":"109","author":"Inman","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2016.10.004_bib47","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11596-009-0116-2","article-title":"Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance","volume":"29","author":"Wang","year":"2009","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.urolonc.2016.10.004_bib48","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 expression as a predictive biomarker in cancer immunotherapy","volume":"14","author":"Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.urolonc.2016.10.004_bib49","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.ctrv.2015.11.001","article-title":"Predictive biomarkers in PD-1\/PD-L1 checkpoint blockade immunotherapy","volume":"41","author":"Meng","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2016.10.004_bib50","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391630309X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814391630309X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:09:05Z","timestamp":1761041345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814391630309X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S107814391630309X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the PD-1\/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}